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Abstract
Background: Previous results have suggested an association of the region of 19q13.3 with several
forms of cancer. In the present study, we investigated 27 public markers within a previously
identified 69 kb stretch of chromosome 19q for association with breast cancer by using linkage
disequilibrium mapping. The study groups included 434 postmenopausal breast cancer cases and an
identical number of individually matched controls.
Methods and Results: Studying one marker at a time, we found a region spanning the gene RAI
(alias PPP1R13L or iASPP) and the 5' portion of XPD to be associated with this cancer. The region
corresponds to a haplotype block, in which there seems to be very limited recombination in the
Danish population. Studying combinations of markers, we found that two to four neighboring
markers gave the most consistent and strongest result. The haplotypes with strongest association
with cancers were located in the gene RAI and just 3' to the gene. Coinciding peaks were seen in
the region of RAI in groups of women of different age.
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In a follow-up to these results we sequenced 10 cases and 10 controls in a 44 kb region spanning
the peaks of association. This revealed 106 polymorphisms, many of which were not in the public
databases. We tested an additional 44 of these for association with disease and found a new tandem
repeat marker, called RAI-3'd1, located downstream of the transcribed region of RAI, which was
more strongly associated with breast cancer than any other marker we have tested (RR = 2.44
(1.41–4.23, p = 0.0008, all cases; RR = 6.29 (1.49–26.6), p = 0.01, cases up to 55 years of age).
Conclusion: We expect the marker RAI-3'd1 to be (part of) the cause for the association of the
chromosome 19q13.3 region's association with cancer.
Background
The search for genetic determinants influencing the risk of
cancer has gained momentum due to the very detailed
maps of the human genome now available. We and others
have previously shown that a region of chromosome
19q13.3 seems associated with a number of cancers,
including cancer of the skin, breast, lung and brain [1-12],
but not testis and colorectal cancer [13,14] Central in this
chromosomal region is a 69 kb stretch, which contains
two genes of importance for DNA repair, XPD (also
known as ERCC2) and ERCC1, one gene presumably
relating to apoptosis, RAI (also known as iASPP or
PPP1R13L), and one presumably involved in ribosomal
RNA transcription, ASE1 alias CD3EAP (see Figure 1).
Thus three of four genes are related to the removal of dam-
aged DNA, an important mechanism in preventing can-
cer.
In the present study, involving 434 breast cancer cases and
an identical number of controls, we initially investigated
27 public markers within the 69 kb stretch for association
with breast cancer, using linkage disequilibrium mapping
based on single markers, as well as on haplotypes combin-
ing several neighboring markers. We found that the region
formed two haplotype blocks, and that associations were
concentrated on the gene RAI in one of these haplotype
blocks. We resequenced 44 kb encompassing this block in
10 cases and 10 controls. Among the 106 found polymor-
phisms (including the 27 described above) we tested an
additional 44 polymorphisms for association with disease
and identified a 5-bases tandem repeat polymorphism,
NT_011109.15 g.18147012dupATTTT(2_11), here called
RAI-3'd1, which discriminates cases from controls better
than any previously investigated polymorphism in this
Schematic representation of the relevant gene regionFigure 1
Schematic representation of the relevant gene region. The crimson arrow marks a chromosomal position. The dark blue 
arrows represent the 4 genes of the region. The numbers below indicate the position relative to the marker XPD-exon23.
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region, and which may well be the effector causing this
haplotype block to associate with cancer.
Results
This investigation deals with breast cancer in women. The
cohort consisted of 24 697 Danish postmenopausal
women age 50 – 64 at inclusion in 1993 – 1997. 434 of
these women developed breast cancer before 2001. The
cases and a set of individually matched controls (see
Methods for details) were analyzed as a nested case-con-
trol study. [9]. All subjects were Caucasians.
We investigated DNA polymorphisms in a 69 kb sub-
region of 19q13.3 for association with breast cancer. To
improve readability each polymorphism investigated was
given a trivial name in accordance with its positions rela-
tive to the nearest gene followed by a hyphen and a serial
number, for instance RAI intron8-3 denotes the third SNP
investigated in the eighths intron of RAI. In the relative
few polymorphisms that were in/dels or repeat polymor-
phisms, the serial number was preceded by a d, for
instance RAI-3'd1. The markers genotyped in this study
are listed in Table 1. We initially typed the ones labelled
L1 and T in the "Series" column. There was no statistical
significant departure from Hardy-Weinberg equilibrium
of any marker among the controls.
Next, we calculated the relative risks of breast cancer and
the corresponding confidence limits for each marker com-
paring the variant homozygotes to homozygotes for the
wildtype allele. However, if the calculation gave an RR
value less than 1, we used the reciprocal value of the RR
and the reciprocal value of the upper confidence limit
instead. This analysis has the advantage that no a priori
assumptions about the distribution of genotypes are
needed. Figure 2 depicts the relative risks and the lower
confidence limits of the relative risks for postmenopausal
breast cancer at all ages as a function of the location of the
markers. The figure also shows the logarithm of the p-val-
ues for trend of association using all 3 genotypes for each
marker. Significant associations (i.e. p-values less than
0.05) of markers with cancer existed in the region from 13
000 to 40 000 bases, covering most of the gene RAI and
the 5' region of the gene XPD. The singular values for the
polymorphism RAI-3'd1 will be discussed later. The corre-
sponding curves for women aged less than 55 showed an
even higher relative risk in the same region with a peak
value of RR = 6.25 (1.72 – 20), p(trend) = 0.005 (results
not shown).
We also used the analytical technique known as haplotype
trend regression [15], more specifically the program
HelixTree, to associate sets of markers with the individual
diseases. We used the entire set of controls for the analy-
ses. This broke the matching of the data sets, but programs
performing haplotype trend regression on individually
matched cohort data are not available, and matching on
other criteria than ethnicity and age may well be irrelevant
for genetic association studies [16]. Figure 3 shows the
overall distribution of p-values for sets of markers plotted
against the position on the chromosome for breast cancer
at all ages. The abscissa of each short haplotype was
defined as the median position of the markers included.
Each curve corresponds to a given size of the marker set,
i.e., the number of markers in the haplotypes. The figure
suggests that the association with breast cancer had two
peaks. One was located at roughly 24 kb and one at 39 kb.
The peaks were clearly present in curves for haplotypes of
2, 3, and 4 neighbouring markers. Larger sets were less
informative, presumably because of increased degrees of
freedom, but they essentially corroborated the results.
When the cases were broken down into cases before and
after age 55, the peak at 24 kb was present in both groups,
whereas the peak at 39 kb only was present in the older
group (results not shown). For comparison, the figure
also contains a singular point corresponding to the best
haplotype, which included the new marker RAI-3'd1, to
be described later.
Finally, we calculated the pair-wise linkage disequilib-
rium of all markers in the controls (Figure 4). The region
consisted of two major haplotype blocks with a few inter-
spersed markers. One haplotype block spanned 16 mark-
ers and 26 kb from XPD exon6 to RAI intron8-3,
corresponding to the region with association to cancer,
whereas the other haplotype block spanned 6 markers
and 9 kb from RAI intron1-1 to ASE1 exon3-3.
Based on all these results we chose to sequence PCR frag-
ments spanning the region from relative position 13 to 59
kb in breast cancer cases and controls. Initially, we
selected 10 cases and 10 controls for analysis. The actual
number of reliable sequences obtained varied somewhat
from one part of the region to the other. Table 9 lists the
106 detected polymorphisms including their positions,
their rs-numbers if assigned, and the surrounding
sequences [See Additional File 1]. Essentially all previ-
ously analyzed polymorphisms were included in the list.
Based on the sequencing results, we analyzed 44 new pol-
ymorphisms using ABI3100, Lightcycler and Sequenom
(designated A, L2 and S in the "Series" column of Table 1).
Among the remainder 18 could not be reproduced and
were probably sequencing errors rather than polymor-
phisms. Most of the remaining could not be assayed for
due to the repetitive nature of the DNA around them. Fif-
teen of the polymorphisms were analyzed by two meth-
ods. The concordance of the two methods was very high.
One polymorphism had a concordance of 98 percent, and
BMC Medical Genetics 2008, 9:56 http://www.biomedcentral.com/1471-2350/9/56
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Table 1: The polymorphisms used in this study, their kind and their identification
New trivial name1 Systematic name2 Series3 rs#4 contig pos5 relativ position6
XPD-exon23 ERCC2 c.2282A>C L1 13181 18123137 0
XPD-exon10 ERCC2 c.965G>A L1 1799793 18135477 12340
XPD-exon6 ERCC2 c.499A>C L1 + S 238406 18136527 13390
XPD-intron5-1 ERCC2 c.492-62T>A S 238407 18136696 13559
XPD-intron5-2 ERCC2 c492-892A>G S 3916809 18137426 14289
XPD-intron5-3 ERCC2 c.391+311A>G S 18139824 16687
XPD-intron3-1 ERCC2 c.278-35G>A L1 1799783 18140254 17117
XPD-5'1 ERCC2 c.-35-113G>C S 3810366 18142160 19023
XPD-5'd1 ERCC2 c.-35-298_-294delGACA L1 + S 3916791 18142345 19208
XPD-5'4 ERCC2 c.-35-583A>C L2 3916788 18142630 19493
XPD-5'd2 ERCC2 c.-35-980_-979ins80 A 3916787 18143027 19890
XPD-5'2 ERCC2 c.-35-1958A>G L1 + S 2097215 18144005 20868
XPD-5'3 g.18145185T>C L1 + S 11878644 18145185 22048
RAI-3'd2 g. 18145752_18145773del(22) A 18145768 22631
RAI-3'8 g.18142233C>A S 18146233 23096
RAI-3'7 g.18146823C>T L1 7252567 18146823 23686
RAI-3'd1 g.18147012ATTTT(2_11) A 7255792 18147012 23875
RAI-3'9 g.18147126T>C L2 2377329 18147126 23989
RAI-3'd3 g.18147199delTT A 3047560 18147192 24055
RAI-3'10 g.18147886T>G S + L2 10422489 18147886 24749
RAI-3'11 g.18148193C>T L2 10426701 18148193 25056
RAI-3'4 g.18150199A>G L1 + S 4544343 18150199 27062
RAI-exon 13-2 PPP1R13L c.*507T>G S 18151158 28021
RAI-exon13-1 PPP1R13L c.*475T>A T + S 6966 18151180 28043
RAI-intron12-1 PPP1R13L c.2515-68G>A S 18151772 28635
RAI-intron12-4 PPP1R13L c.2515-330G>C S 18152034 28897
RAI-intron12-3 PPP1R13L c.2515-467G>A L1 10417235 18152171 29034
RAI-intron12-5 PPP1R13Lc.2515-1150G>A L2 12876252 18152764 29627
RAI-intron12-2 PPP1R13L c.2514+505T>A L1 8112723 18153497 30360
RAI-intron11-2 PPP1R13L c.2315-594T>G S 18154796 31659
RAI-intron11-1 PPP1R13L c.2315-1281G>A L1 + S 2017104 18155483 32346
RAI-intron11-2 PPP1R13L c.2248+1167G>T S 18155871 32734
RAI-intron8-1 PPP1R13L c.1882-1425A>G L1 1970764 18159091 35954
RAI-intron8-10 PPP1R13L c.1882-1263A>G S 18159263 36126
RAI-intron8-9 PPP1R13L c.1882-1697A>G L2 18160363 37226
RAI-intron8-4 PPP1R13L c.1882-2270T>G S 18160936 37799
RAI-intron8-5 PPP1R13L c.1882-2271G>C S 18160937 37800
RAI-intron8-11 PPP1R13l c.1881+1912G>T S 18161433 38296
RAI-intron8-6 PPP1R13L c.1881+1514A>G S 18161841 38704
RAI-intron8-2 PPP1R13L c. 1881+1149B>A L1 6509210 18162206 39069
RAI-intron8-12 PPP1R13l c.1881+756C>T L2 12986272 18162599 39462
RAI-intron8-7 PPP1R13L c 1881+452T>G S 18162903 39766
RAI-intron8-8 PPP1R13L c.1881+389T>C S 18162986 39849
RAI-intron8-3 PPP1R13L c.1881+385T>G L1 18162970 39833
RAI-intron7-1 PPP1R13L c.1421-1236G>C S 18165052 41915
RAI-intron3-2 PPP1R13L c.264-404G>A L1 4803814 18168944 45807
RAI-intron3-3 PPP1R13L c.264-408G>A L1 4803815 18168948 45811
RAI-intron1-5 PPP1R13L c.-21-1304insTAAG S 18171119 47982
RAI-intron1-7 PPP1R13L c.-21-1931G>T S 10402584 18171746 48609
RAI-intron1-10 PPP1R13Lc.-21-2062G>A S 10401293 18171815 48678
RAI-intron1-1 PPP1R13L c.-21-2169A>G L1 + S 4572514 18171984 48847
RAI-intron1-4 PPP1R13L c.-21-3291G>A L2 + S 4803816 18173106 49969
RAI-intron1-8 PPP1R13L c.-21-3291A>G S 18173107 49970
RAI-intron1-2 PPP1R13L c.-22+1148C>T L1 2226949 18175327 52190
RAI-intron1-3 PPP1R13L c.-22+734A>G L2 959457 18175739 52602
RAI-intron1-9 PPP1R13L c.-22+379T>C S 18176096 52959
RAI-intron1-5 PPP1R13L c.-22+297T>C L2 + S 4803817 18176178 53041
RAI-5'1 PPP1R13L c-54-177T>C L1 + S 10412761 18176680 53543
ASE1-exon1 CD3EAP c.-468-21G>A L1 967591 18178152 55015
BMC Medical Genetics 2008, 9:56 http://www.biomedcentral.com/1471-2350/9/56
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ASE1-exon2 CD3EAP c.22+29A>C S 18178222 55085
ASE1-exon3-4 CD3EAP c.564G>C S 18178623 55486
ASE1-exon3-1 CD3EAP c.1264A>G T 735482 18180220 57083
ASE1-exon3-2 CD3EAP c.1605A>G L1 + S 762562 18180561 57424
ASE1-exon3-3 CD3EAP c.1668G>A T + S 2336219 18180624 57487
ASE1-exon3-d1 CD3EAP c.1751TTC(5_6) A 3212987 18180707 57570
ASE1-exon3-6 CD3EAP c.1998C>A L1 + S 3212986 18180954 57817
ASE1-exon3-4 CD3EAP c.*1228T>C L2 3212983 18182205 59068
ERCC1-exon4 ERCC1 c.500T>C L1 11615 18191871 68734
1) The trivial names have been changed to conform to the new model of the RAI gene, which involves a major 5' extension of the gene relative to 
older models. Specifically, the polymorphism previously called RAI intron1 is now called RAI-intron8-1. Similarly RAI exon6 is now called RAI-
exon13-1.
2) The systematic name according to http://www.hgvs.org/mutnomen/recs.html
3) The series of assays to which the polymorphism belongs
L1: First series of Lightcycler assays
L2: Later series of Lightcycler assays
A: Assays on ABI3100
T: Assays on Taqman
S: Assays on Sequenom
4) The rs-number of the polymorphisms in NCBI's database dbSNP
5) Positions of the polymorphisms in the contig [GenBank: NT_011109.15]
6) Positions of the polymorphisms relative to XPD-exon23
Table 1: The polymorphisms used in this study, their kind and their identification (Continued)
Association of single polymorphisms with breast cancer, all agesFigure 2
Association of single polymorphisms with breast cancer, all ages. The relative risk for cancer of the two homozygotes (Dark 
blue), the lower confidence limit for the relative risk(Pink), and the negative logarithm to the p-trend for association of all 3 
genotypes(Light blue) of each marker with cancer is depicted against the position of the marker. The singular points represent 
the values for RAI-3'd1.
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-log(p-trend)
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the remainder had concordance rates of 99 percent or
above.
A new tandem repeat polymorphism, RAI-3'd1 was partic-
ularly interesting. It was located close to minimum p
value of the haplotype trend regression analysis and it had
the potential to modify gene expression by virtue of the
relative large change in the sequence. To simplify the scor-
ing we subdivided the fragments of RAI-3'd1 into two
groups, 6 repeats or less, called S for short, and 7 repeats
or more, called L for long. The results are shown in Table
2. RAI-3'd1, showed a stronger association with disease
than any other polymorphism we have tested (singular
point in figure 2). The calculated relative risk was higher
(RR = 2.44 (1.41–4.23) and the associated p-value was
lower (p = 0.0008) than any we had observed before.
When the effect was broken down into age brackets, RAI-
3'd1 was marginally better (RR = 6.29 (1.49–26.6)) than
other markers in the youngest age group and showed a
clearer tendency in the other age groups (see Table 2).
Another interesting polymorphism, RAI-3'd2, was also
associated with disease, albeit to a lesser extent. Moreover,
when adjusting RAI-3'd2 for RAI-3'd1 we lost all associa-
tion of the former with cancer, whereas RAI-3'd1
remained associated with cancer after adjustment for RAI-
3'd2. This suggested that RAI-3'd2 was only indirectly
associated with cancer, for instance through its linkage
disequilibrium with RAI-3'd1.
We also performed haplotype trend regression on RAI-
3'd1 and it's neighboring SNPs. One of the haplotypes,
RAI-3'd1 RAI-3'd3 RAI-3'4, gave a lower overall p-value
(p= 0.0002) than any we had seen (indicated as the singu-
lar value in Figure 3).
To better understand the nature of the association, we tab-
ulated the frequencies of individual haplotypes made up
of the 3 neighbouring markers centring on the position at
24 kb with maximal evidence of association with breast
cancer (RAI-3'd1 RAI-3'd3 RAI-3'4, see above and
Table 2: Association of breast cancer with two additional polymorphisms selected from those detected by sequencing.
Polymorphism N1 cases N1 controls IRR2 (95% CI3) P-trend4
RAI-3'd1
All ages 0.0008
LL 38 59 1
SL 127 165 1.39 (0.81–2.38)
SS 200 150 2.44 (1.41–4.23)
<55 yr 0.01
LL 5 15 1
SL 18 25 1.46 (0.33–6.47)
SS 33 14 6.29 (1.49–26.61)
55–60 yr 0.19
LL 12 17 1
SL 45 63 1.72 (0.63–4.73)
SS 61 49 2.57 (0.88–7.48)
>60 yr 0.12
LL 21 27 1
SL 64 77 1.09 (0.52–2.60)
SS 106 87 1.73 (0.83–3.64)
RAI-3'd2
All ages 0.005
LL 149 113 1
SL 168 199 0.62 (0.44–0.88)
SS 66 88 0.50 (0.32–0.79)
1) Number of persons
2) Incidence rate ratio
3) Confidence limit
4) P-value for trend among the IRRs for all 3 genotypes
BMC Medical Genetics 2008, 9:56 http://www.biomedcentral.com/1471-2350/9/56
Page 7 of 12
(page number not for citation purposes)
Association of sets of neighbouring SNPs with breast cancerFigure 3
Association of sets of neighbouring SNPs with breast cancer. The overall p-value for the association of a set of markers as cal-
culated by HelixTree is depicted against the median position of the markers. The singular point represent the value for the hap-
lotype RAI-3'd1 RAI-3'd3 RAI-3'4. (Blue), haplotypes made up of 2 neighboring polymorphisms. (Red), haplotypes made up of 3 
neighboring polymorphisms. (Green), haplotypes made up of 4 neighboring polymorphisms.
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Median position of haplotype (bases)
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4-haplo
RAI-3'd1 RAI-3'3 RAI-3'4
Table 3: Frequency of haplotypes in breast cancer cases and controls and p-values for their association with cancer as determined by 
haplotype trend regression.
Breast cancer cases Breast cancer controls
Haplotype/Agegroup Young1) Old2) All ages All ages
RAI-3'd1s RAI-3'd3s RAI-3'4c 0.0353 (0.37)4 0.054 (0.002) 0.051 (0.003) 0.022
RAI-3'd1s RAI-3'd3s RAI-3'4t 0.001 (-) 0.002 (0.12) 0.002 (0.09) 0.000
RAI-3'd1s RAI-3'd3l RAI-3'4c 0.008 (0.12) 0.006 (0.11) 0.006 (0.07) 0.001
RAI-3'd1s RAI-3'3dl RAI-3'4t 0.712 (0.02) 0.631 (0.17) 0.642 (0.06) 0.597
RAI-3'd1l RAI-3'd3s RAI-3'4c 0.244 (0.006) 0.297 (0.003) 0.290 (0.0005) 0.379
RAI-3'd1l RAI-3'd3s RAI-3'4t 0.000 (-) 0.005 (0.04) 0.005 (0.01) 0.000
RAI-3'd1l RAI-3'd3l RAI-3'4c 0.000 (-) 0.000 (0.61) 0.000 (0.11) 0.000
RAI-3'd1l RAI-3'd3l RAI-3'4t 0.000 (0.69) 0.003 (0.48) 0.003 (0.57) 0.001
RAI intron8-2a RAI intron8-3a 0.259 (0.78) 0.209 (0.01) 0.216 (0.02) 0.271
RAI intron8-2a RAI intron8-3c 0.000 (0.89) 0.007 (0.13) 0.006 (0.13) 0.000
RAI intron8-2g RAI intron8-3a 0.69 (0.12) 0.701 (0.001) 0.699 (0.0007) 0.615
RAI intron8-2g RAI intron8-3c 0.051 (0.05) 0.084 (0.11) 0.079 (0.04) 0.113
1) Breast cancer before age 55
2) Breast cancer at age 55 or older
3) Haplotype frequency
4) P-value for haplotype frequency in comparison to the haplotype frequency of controls, all ages.
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Table 3). We also tabulated p-values associated with the
individual frequencies. The same haplotypes in young
and older cancer cases differed in frequency from the con-
trols (RAI-3'd1LRAI-3'd3S RAI-3'4C protective; whereas all
haplotypes containing RAI-3'd1S seemed inductive).
Finally, as a preliminary check of our results we have
tested RAI-3'd1 in a small independent sample of Danish
women from Funen with breast cancers (Cold, unpub-
lished). We found the persons that were RAI-3'd1SS to
have an increased risk of breast cancer between 50 and 60
years of age (Table 4). A similar, but non-significant ten-
dency was present in subjects under age 50, whereas no
association between alleles of RAI-3'd1 and breast cancer
was present after age 60.
Discussion
This study continues our studies of the association of
breast cancer with one particular chromosomal region,
19q13.3, more specifically the gene RAI and its immediate
surroundings. The present results improve the chromo-
somal resolution and suggest a possible effector, i.e. a
causative variant. In addition, the haplotype analysis pre-
sented is the first evidence for association of RAI with
breast cancer after age 55. It does so with p-values around
10-3 at the same location as the analysis of younger per-
sons, a testament to the efficiency of analyzing haplotypic
associations rather than single SNPs. With this finding our
results become relevant for a much larger group of cancer
patients.
Most of our data come from a population-based follow-
up study in Denmark with very limited dropout. Although
this nested case-control study was originally individually
matched, we have sometimes treated it as an unmatched
case-control study in order to be able to use current com-
puter programs. This opens the possibility of confounding
from the matching parameters. For two reasons, however,
we find such confounding highly unlikely. First, the
observed effects are generally too strong for confounding
to be a reasonable explanation. Second, confounders
must correlate with the primary variables. We have no rea-
son to believe that any of the match criteria correlated
with the constitution on chromosome 19.
We used several ways to try to locate the effector(s). The
overall conclusion was clear: One effector is located in the
haplotype block between the markers XPD exon6 and RAI
intron8-3. Details of the results varied: Methods handling
one marker at a time indicated that the effector could be
located anywhere from the 5' portion of XPD to the 5' por-
tion of RAI, whereas analyses combining information
from multiple markers indicated the presence of two
effectors; one was located just 3' to the gene RAI, and
Table 4: Breast cancer risk in an independent small cohort of Danish Women in relation to RAI-3'd1. 
Age at diagnosis RAI-3'd1SS RAI-3'd1SL + RAI-3'd1LL OR1 (95% CI2) (one-sided) P-value3 (one-sided)
< 50 years cases 9 14 1.36 (0.51 -) 0.30
controls 9 19
50 – 60 years cases 13 9 2.50 (1.02 -) 0.04
controls 15 26
>= 60 years cases 30 44 0.89 (0.46 -) 0.88
controls 32 38
The table lists the number of persons in each group, the odds ratio and the lower 5 percent confidence limit for the distribution of persons, and the 
p-value for the odds ratio.
1) Odds Ratio for cases and controls combined with genotypes
2) One-sided lower 95% Confidence Limit for the OR
3) One-sided P-value for the OR
Pair-wise linkage disequilibrium between all markers in the controlsFigure 4
Pair-wise linkage disequilibrium between all markers in the 
controls. The values above the diagonal are the correlations 
of two polymorphisms, R. The values below the diagonal are 
Nowontin's normalised linkage disequilibrium, D'. The red 
color represent high values, blue represents low value.
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another was located in the 5' portion of the gene (at 39
kb).
We resequenced the region of strongest association iden-
tified by haplotype trend regression. Here we discovered a
new 5-base tandem repeat polymorphism, RAI-3'd1, that
showed even stronger association with cancer (p =
0.0008). Bonferroni adjustment for the multiplicity of
testing indicates that with an average correlation of 0.32
among a total of 68 polymorphisms, any p-value below
0.003 will make the whole set significant [17]). Thus, the
result cannot be considered a result of the multiplicity of
testing.
The polymorphism RAI-3'd1 may well be the effector. The
haplotype data of Table 3 indirectly supports this view. All
haplotypes in Table 3 containing RAI-3'd1S were associ-
ated with increased risk of cancer, irrespective of the sur-
rounding polymorphisms. We would not expect this
result if RAI-3'd1 only was a correlate of the effector. How-
ever, mapping inside the haplotype block with the use of
data from the present population is not very sensitive. For
instance, the markers XPD-5'2 and RAI intron11, spaced
12 kb apart, were synonymous in 799 of 813 persons.
Studies of this polymorphism in populations of different
ethnicity could prove very useful, but functional assays
will be necessary before a final conclusion can be reached.
It may be useful to compare aspects of the breast cancer
risk caused by the RAI region with that caused by the
BRCA genes. The RAI region is either recessive or suffers
from strong haplo-insufficiency, and it roughly doubles
the risk of breast cancer, thus the penetrance is low. The
BRCA genes on the other hand are dominant, and they
increase the breast cancer risk about 8 fold, i.e. penetrance
is high. However, the risk allele of RAI is very common. In
our study approximately 40 percent of the controls were
homozygotes for the risk allele. A conservative estimate of
the ethiological fraction suggests that at least 20 percent of
breast cancers is caused by RAI-3'd1, and the number may
be twice as high. Thus in terms of the number of cancers
caused in the Danish population, RAI seems to exceed the
BRCA genes in importance.
From Table 3 it is apparent that in the Danish population,
and presumably in other Caucasian populations as well,
the risk allele, RAI-3'd1S, occurred with different neigh-
boring SNP alleles at reasonable frequencies. In contrast
the protective allele RAI-3'd1L almost exclusively occurred
together with RAI-3'd3S and RAI-3'4C. Further investiga-
tion has shown that this tendency was reproduced with a
number of the surrounding SNPs. Generally, the less fre-
quent haplotypes involving RAI-3'd1S were approximately
10 fold more common than the less frequent haplotypes
involving RAI-3'd1L were. This was true for 12 out of 14
SNPs in the 23 kb interval from XPD exon6 to RAI
intron8-1. The exceptions were RAI-e13 and RAI-3'7. In
accordance, combined analysis of the 12 SNPs using
HelixTree to form a 12 point haplotype indicated that 13
less frequent haplotypes involving RAI-3'd1S constituted
23 percent of the chromosomes, corresponding to 56 per-
cent of the major haplotype with RAI-3'd1S. In contrast, 7
less frequent alleles involving RAI-3'd1L only constituted
2 percent of the chromosomes, corresponding to only 8
percent of the major haplotype with RAI-3'd1L (results not
shown). Thus, the haplotypes containing RAI-3'd1S seem
more diverse than their counterparts containing RAI-3'd1L
do. The simple interpretation of this phenomenon would
be that RAI-3'd1S is the ancestral allele in Caucasians.
There are at present no known polymorphisms affecting
the amino acid sequence of the RAI protein. Presumably,
RAI-3'd1 influences the expression of RAI. Our hypothesis
is that RAI-3'd1 modulates a silencer or enhancer. The
influence of RAI-3'd1 may not be limited to RAI. It is a
curious fact that this short stretch of chromosome 19,
comprising only 69 kb, contains two DNA repair genes
and one apoptosis gene. One could imagine some sort of
higher-order control common for this cluster of related
genes. Studies of the expression of XPD, RAI and ERCC1
in lymphocytes from humans have indeed shown that
their mRNA levels are tightly coordinated [18,19].
If a primary effect of RAI-3'd1 is modified RAI expression,
one result should be modified apoptosis. RAI protein is an
inhibitor of RelA, a subunit of the transcription factor NF-
κB [20,21]. NF-κB has long been implicated in both cell
proliferation and apoptosis. Modulation of NF-κB may
well be part of a "crunch-time scenario", invoked when
the cell has to muster its forces and make life-and-death
decisions. A recent report suggested that the choice
between cell survival and death is regulated by the relative
activity of the two subunits encoded by RelA and c-rel [22].
By neutralising the RelA product, RAI protein would pre-
sumably shift this balance towards apoptosis. In accord-
ance with this view, we have found that RAI mRNA
increases dramatically when cells undergo apoptosis. We
have also found that simultaneous transfection with siR-
NAs destabilizing RAI mRNA reduces apoptosis in non-
transformed cells. Thus, we believe that RAI expression is
instrumental for apoptosis [23]. However, RAI protein
may also block p53 activity and thus have the opposite
effect [24]. For instance, RAI is over-expressed in certain
tumors and may in this situation block apoptosis. We
have previously found that the expression of RAI is ca. 8-
fold higher in both preneoplastic lesions such as adeno-
mas and in tumour tissue such as adenocarcinomas com-
pared to healthy tissue from the same person [25].
Furthermore, we have found that over-expression of RAI
enhances the malignant character of oncogene-trans-
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formed cells (M. Laska et al, manuscript in preparation).
Thus, RAI may alternatively accelerate or inhibit cell
growth depending on the circumstances.
The previous reports, that have associated our region of
interest with the risk of getting basal cell carcinoma,
melanoma, lung cancer, glioma, breast cancer, bladder
cancer, and possibly head and neck cancer [1-10,26,27],
suggest that the effector may influence the risk of getting a
wide variety of cancers of different etiology. This conclu-
sion makes perfect sense if the functional elements mod-
ulate a downstream cellular response, such as apoptosis.
Conclusion
We found the region around the RAI gene to be strongly
associated with breast cancer, in particular during the
early menopause. The marker RAI-3'd1 may be the cause
for the extra risk for breast cancer. We think it may modu-
late an enhancer or silencer influencing RAI and possibly
other genes.
Methods
Ethical compliance
This study was performed in compliance with the Helsinki
declaration. The project was approved by the Science Eth-
ical Committee of Copenhagen (j.nr: 01-345/93/(KF) 11-
037/01/11-124/01). Written and verbal informed consent
was obtained from all participants.
Study groups
"Diet, Cancer and Health" is a Danish prospective follow-
up study [28]. Individuals eligible for inclusion were born
in Denmark, living in the Copenhagen or Aarhus areas,
and at the time of inclusion had not been registered as
having cancer (including non-melanoma skin cancer) in
the Danish Cancer Registry. Invited to participate were
160 725 individuals, aged 50 to 64 years, of whom 57 053
were recruited. Among these, 542 were later registered
with the Danish Cancer Register with a cancer diagnosed
before the date of enrolment and were therefore excluded.
At enrolment (1993–1997), detailed information was col-
lected on diet, smoking habits, lifestyle, weight, height,
children, medical treatment, and other socio-economic
characteristics and environmental exposures. For women,
information regarding hormone replacement therapy
(HRT) and menopausal status was also recorded. Moreo-
ver, blood, urine, fat tissue, and other biological materials
were sampled and stored at -150°C. Cohort members
were identified by a unique identification number, allo-
cated to every Danish citizen by the Central Population
Registry. Cohort members were linked to the Central Pop-
ulation Registry for information on vital status and immi-
gration. Information on cancer occurrence among cohort
members was obtained through record linkage to the
Danish Cancer Registry, which collects information on all
inhabitants in Denmark who develop cancer [29]. Link-
age was performed by use of the personal identification
number.
The study sample for breast cancer included the 29 549
women recruited within "Diet, Health and Cancer". Eight
women were excluded from the study because they did
not fill in the lifestyle questionnaire. Because the present
analysis aimed at the subgroup of women who were post-
menopausal at study entry, we excluded 4844 supposedly
pre-menopausal women, including 4798 women who
had reported at least one menstruation no more than 12
months before entry and no use of HRT, nine women who
gave a lifetime history of no menstruations, and 37
women who did not answer the questions about current
or previous use of HRT, leaving 24 697 postmenopausal
women.
Each cohort member was followed up for breast cancer
occurrence from the date of entry, i.e. date of visit to the
study centre until the date of diagnosis of any cancer
(except for non-melanoma skin cancer), date of death,
date of emigration, or 31 December 2000, whichever
came first. A total of 434 women were diagnosed with
incident breast cancer during the follow up period. Con-
trols were selected among the remaining cohort partici-
pants using a nested case-control approach. One control
was selected for each of the 434 cases. The control was
cancer-free at the exact age at diagnosis of the case and was
further matched on age at inclusion into the cohort (half-
year intervals), certainty of postmenopausal status
(known/probably postmenopausal), and use of HRT at
inclusion into the cohort (current/former/newer). Of the
434 pairs (866 women; 434 cases and 434 controls,
including two cases), 19 pairs were excluded due to lack
of blood sample in either case or control, leaving 415
pairs for study. Additional pairs were excluded due to
problems with the genotyping procedure in one or both
members of the pair.(RAI-3'd1 105 pairs; RAI-3d'2 62
pairs).
Resequencing of genomic DNA
Resequencing was performed on PCR fragments from
DNA of persons selected for different haplotypes among
the known markers in the region. 7 of the cases were fur-
ther selected for having gotten breast cancer before age 55.
The DNA sequences to be amplified and resequenced
were obtained from databases. Repetitive sequences were
determined and masked using RepeatMasker software.
Primers were chosen using Primer3 software. PCR ampli-
fication was performed in a 10 μL volume and the product
was purified with Centricon 100 (Ambion). Each
sequencing reaction contained 2.5 μL of the purified PCR
product, 6.5 μL of water, 2.0 μL of BigDye version 3 mix
(Applied Biosystems), and 1.0 μL of 5× sequencing buffer,
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according to the protocol of the dye manufacturer. Elec-
trophoresis and sequencing detection were performed
using an ABI PRISM 3730 × l DNA Analyzer (Applied Bio-
systems).
Typing of SNPs
Table 1 lists the polymorphisms used in this study, their
nature, the numbers in the NCBI database dbSNP, the
method and time of typing, and their position therein,
and their relative position within the region of interest.
Typing was performed on a Lightcycler, a Taqman and a
Sequenom. Three polymorphism, RAI-3'd1, RAI-3'd3,
and RAI-3'd2 were determined as length polymorphisms
on an ABI3100 (Applied Biosystems, Nærum, Denmark).
Information about the assay conditions can be found in
the Additional File 1: SNP typing and SNP identification.
Statistics
Data recording, calculations and tests of allele frequencies
were performed in SPSS and Excel. Calculation of the rel-
ative risk and confidence intervals for the single polymor-
phisms was done using the procedure phrec in the
program package SAS (SAS Institute, Cary, NC, USA).
Simultaneous analysis of multiple SNPs employing hap-
lotype trend regression [15] was performed with Helix-
Tree (GoldenTree, Bozeman, MT, USA). Three programs
were used for assigning haplotypes to individuals on the
bases of genotype data: HelixTree, Arlequin [30] and
Phase [31]. Arlequin like HelixTree is a maximum likeli-
hood algorithm, whereas Phase also includes a penalty for
each new haplotype that is brought into play. Further-
more, Arlequin includes missing values in its table of fre-
quencies. To compensate for the latter, we normalised the
values corresponding to fully defined haplotypes before
including them in the analysis. All three were run under
Windows 2000. HelixTree and Arlequin produced almost
identical data. The data from Phase were also similar to
those of the other programs. Helix Tree's values were used
in the further calculations. The figure of the linkage dise-
quilibrium among the controls (Figure 4) was also
derived from HelixTree.
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